Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GUSB | P08236 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8875118 | 0.82 | SMN1; SMN2 (0.41) | KMT2AMEN1PDE10AGRM2POLB | |
| SCHEMBL7795326 | 0.81 | KMT2A (0.44) | KMT2AMEN1PDE10APOLBMAPT | |
| SCHEMBL1054774 | 0.81 | MEN1 (0.49) | KMT2AMEN1PDE10APOLBMAPT | |
| SCHEMBL38661829 | 0.81 | MEN1 (0.49) | KMT2AMEN1PDE10APOLBMAPT | |
| SCHEMBL7049459 | 0.81 | KMT2A (0.47) | KMT2AMEN1CDK9DYRK1ADYRK2 | |
| SCHEMBL4623903 | 0.80 | THRA (0.54) | — | |
| SCHEMBL7048368 | 0.80 | MEN1 (0.45) | KMT2AMEN1PDE10APOLBMAPT | |
| SCHEMBL12096583 | 0.79 | PLA2G2A (0.46) | KMT2AMEN1CDK9DYRK1ADYRK2 | |
| SCHEMBL5705535 | 0.78 | MAPT (0.50) | KMT2AMEN1PDE10APOLBMAPT | |
| SCHEMBL1602466 | 0.78 | BACE1 (0.41) | KMT2AMEN1PDE10APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082279-A1 | Chemiluminescent Compounds | GEN-PROBE INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082279-A1 | Chemiluminescent Compounds | GEN-PROBE INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082279-A1 | Chemiluminescent Compounds | GEN-PROBE INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| EP-1658503-B1 | CHEMILUMINESCENT COMPOUNDS | MOLECULAR LIGHT TECH RES LTD (GB) | 2009-11-18 | — | — | EP | disclosed |
| US-20070166759-A1 | Chemiluminescent compounds | GEN-PROBE CARDIFF, LTD. (GB) | 2007-07-19 | — | — | US | disclosed |
| US-20070166759-A1 | Chemiluminescent compounds | GEN-PROBE CARDIFF, LTD. (GB) | 2007-07-19 | — | — | US | disclosed |
| US-20070166759-A1 | Chemiluminescent compounds | GEN-PROBE CARDIFF, LTD. (GB) | 2007-07-19 | — | — | US | disclosed |
| EP-1658503-A1 | CHEMILUMINESCENT COMPOUNDS | Molecular Light Technology Research Limited (GB) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005022161-A1 | CHEMILUMINESCENT COMPOUNDS | MOLECULAR LIGHT TECHNOLOGY RESEARCH LIMITED (GB) | 2005-03-10 | — | — | WO | disclosed |
| EP-0609885-B1 | Acridinium compounds and conjugates thereof | MOCHIDA PHARM CO LTD (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-5594112-A | CHEMILUMINESCENCE LABEL | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-14 | — | — | US | disclosed |
| US-5438139-A | Chemiluminescent; useful as immunolochemical, DNA probe and receptor bininding assays | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1995-08-01 | — | — | US | disclosed |
| EP-0609885-A1 | Acridinium compounds and conjugates thereof | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070166759-A1 | Chemiluminescent compounds | CBR3, CBR1, LTC4S | KMT2A 3854/4885MEN1 2101/4885CDK9 3431/4885 |
| US-20110082279-A1 | Chemiluminescent Compounds | CBR3, LTC4S, CBR1 | KMT2A 3896/4885MEN1 1714/4885CDK9 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.